Can IodixAnol ReducE the Incidence of Adverse Renal or Cardiac Events in Chronic Total Occlusion Interventions (CARE-CTO): A Substudy of the PROGRESS-CTO Registry
Journal of Invasive Cardiology · 2025
DOI: 10.25270/jic/25.00004 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Invasive Cardiology, 2025. Verfasst von Dimitrios Strepkos und 24 weiteren Autor:innen. Beteiligte Einrichtung: Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota. Hauptthemen laut MEDLINE: Acute Kidney Injury, Coronary Occlusion, Percutaneous Coronary Intervention, Postoperative Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
OBJECTIVES: The impact of contrast type in chronic total occlusion (CTO) percutaneous coronary intervention (PCI) remains controversial. The authors sought to evaluate the impact of contrast medium selection on patients undergoing CTO PCI. METHODS: The authors examined the outcomes of patients who underwent CTO PCI using iso-osmolar (iodixanol) vs pooled low-osmolar contrast media (LOCM) using data from the PROGRESS-CTO registry. RESULTS: Iodixanol was used in 1007 (18.1%) of 5558 CTO PCIs. Compared with pooled LOCM, iodixanol-treated patients were more likely to be women, were older, and more likely to have diabetes, dyslipidemia, hypertension, history of heart failure, myocardial infarction, coronary artery bypass graft surgery, and stroke. Iodixanol cases had higher complexity, with longer lesion length (35.25 ± 25.16 vs 28.91 ± 19.46 mm, P less than .001), higher prevalence of moderate or severe calcification (43% vs 37%, P less than .001) and moderate or severe proximal tortuosity (30% vs 24%, P less than .001), and higher Japanese-CTO (2.52 vs 2.17, P less than .001) and PROGRESS-CTO scores (1.30 vs 1.16, P less than .001). Iodixanol cases required longer procedure times but similar contrast volumes. Technical (85.3% vs 89.2%, P = .001) and procedural success (83.4% vs 87.3%, P = .001) were lower in iodixanol cases. Acute kidney injury (AKI) occurred in 6.4% of cases. After propensity score matching, the patients who received iodixanol had lower incidence of AKI (odds ratio [OR]: 0.67; 95% CI, 0.47, 0.97; P = .032) and a trend for lower incidence of major adverse renal or cardiovascular events (OR: 0.75; 95% CI, 0.56, 1.0; P = .061). CONCLUSIONS: AKI occurred in approximately 6% of CTO PCI cases. Iodixanol use was associated with a lower incidence of AKI, despite being used in more complex patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota.
- Henry Ford Cardiovascular Division, Detroit, Michigan.
- Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia.
- Cleveland Clinic, Cleveland, Ohio.
- Memorial Bahcelievler Hospital, Istanbul, Turkey.
- University Hospitals, Case Western Reserve University, Cleveland, Ohio.
Zitieren
APA
Strepkos, D., Rempakos, A., Alexandrou, M., Mutlu, D., Carvalho, P. E. P., Ser, O. S., Alaswad, K., Basir, M. B., Khelimskii, D., Krestyaninov, O., Khatri, J. J., Young, L., Goktekin, O., Poommipanit, P., Jaffer, F., Gorgulu, S., ElGuindy, A. M., Abi Rafeh, N., Mastrodemos, O., …, & Brilakis, E. S. (2025). Can IodixAnol ReducE the Incidence of Adverse Renal or Cardiac Events in Chronic Total Occlusion Interventions (CARE-CTO): A Substudy of the PROGRESS-CTO Registry. Journal of Invasive Cardiology. https://doi.org/10.25270/jic/25.00004
Vancouver
Strepkos D, Rempakos A, Alexandrou M, Mutlu D, Carvalho PEP, Ser OS, et al. Can IodixAnol ReducE the Incidence of Adverse Renal or Cardiac Events in Chronic Total Occlusion Interventions (CARE-CTO): A Substudy of the PROGRESS-CTO Registry. Journal of Invasive Cardiology. 2025. doi:10.25270/jic/25.00004
BibTeX
@article{Strepkos2025,
author = {Strepkos, Dimitrios and Rempakos, Athanasios and Alexandrou, Michaella and Mutlu, Deniz and Carvalho, Pedro E P and Ser, Ozgur Selim and Alaswad, Khaldoon and Basir, Mir B and Khelimskii, Dmitrii and Krestyaninov, Oleg and Khatri, Jaikirshan J and Young, Laura and Goktekin, Omer and Poommipanit, Paul and Jaffer, Farouc and Gorgulu, Sevket and ElGuindy, Ahmed M and Abi Rafeh, Nidal and Mastrodemos, Olga and Rangan, Bavana V and Jalli, Sandeep and Voudris, Konstantinos and Sandoval, Yader and Burke, M Nicholas and Brilakis, Emmanouil S},
title = {Can IodixAnol ReducE the Incidence of Adverse Renal or Cardiac Events in Chronic Total Occlusion Interventions (CARE-CTO): A Substudy of the PROGRESS-CTO Registry},
journal = {Journal of Invasive Cardiology},
year = {2025},
doi = {10.25270/jic/25.00004}
}
EUVIMED